Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055756 | 0.86 | MAPT (0.45) | KDM4EGAAMOGAT2TRPM8TAS1R3 | |
| SCHEMBL3955850 | 0.85 | KDM4E (0.41) | KDM4EGAAMOGAT2TRPM8TAS1R3 | |
| SCHEMBL3953865 | 0.84 | CNR2 (0.39) | KDM4ETAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL3954029 | 0.82 | KDM4E (0.42) | KDM4EGAAMOGAT2TRPM8TAS1R3 | |
| SCHEMBL4048954 | 0.80 | MAPT (0.51) | GAAMOGAT2TRPM8TAS1R3TAS1R1 | |
| SCHEMBL4054586 | 0.78 | TRPM8 (0.50) | KDM4EGAATRPM8ALDH1A1 | |
| SCHEMBL4048435 | 0.77 | MAPT (0.41) | KDM4EGAATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3949067 | 0.76 | TRPM8 (0.59) | TRPM8ALDH1A1PKM | |
| SCHEMBL3950797 | 0.75 | MOGAT2 (0.43) | KDM4EGAAMOGAT2TAS1R3TAS1R1 | |
| SCHEMBL4050143 | 0.75 | MAPT (0.47) | GAATAS1R3TAS1R1TAS1R2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032754-A2 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062253-A1 | HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | KDM4E 2542/4885GAA 3799/4885MOGAT2 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.